TCGA-50-5055-01A-01R-1628-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_GAMMA_RESPONSE+0.490
- INTERFERON_ALPHA_RESPONSE+0.480
- IL6_JAK_STAT3_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INFLAMMATORY_RESPONSE+0.400
- COAGULATION+0.390
- KRAS_SIGNALING_UP+0.380
- COMPLEMENT+0.370
- TNFA_SIGNALING_VIA_NFKB+0.340
Top 10 suppressed
- G2M_CHECKPOINT-0.560
- E2F_TARGETS-0.520
- MITOTIC_SPINDLE-0.490
- MYC_TARGETS_V2-0.390
- MTORC1_SIGNALING-0.340
- GLYCOLYSIS-0.290
- MYC_TARGETS_V1-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.260
- PROTEIN_SECRETION-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5045-01A-01R-1628-07 | — | cohortA1 | 0.941 |
| 2 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.905 |
| 3 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.898 |
| 4 | 97a6e3bc-f272-4d88-a1fe-ef3541cdf296 | — | — | 0.877 |
| 5 | TCGA-34-5234-01A-01R-1635-07 | — | cohortSQ1 | 0.874 |
| 6 | TCGA-CN-6017-01A-11R-1686-07 | — | — | 0.874 |
| 7 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.869 |
| 8 | TCGA-FD-A5BS-01A-21R-A26T-07 | — | — | 0.869 |
| 9 | SRR2016962 | — | — | 0.861 |
| 10 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |